Kornimate/medical-research-clean huggingface dataset:
efficacy of an exercise program for patients with femoro-acetabular impingement

Conditions: Femoracetabular Impingement

Summary: the purpose of this study is to examine whether using an exercise regime on people with femoroacetabular impingement (fai) can help reduce pain and improve function. also, it examines whether the exercise regime will help prevent the worsening of hip cartilage deterioration.

a significant proportion of adults from ages 18 to 50 have a deformity in the neck of their femur. this can be painful and is called a femoroacetabular impingement (fai), and could lead to ones cartilage being destroyed and possibly lead to osteoarthritis of the hip. people with this deformity in their femur have been found to move their hips differently when doing tasks such as walking, squatting or climbing stairs compared to those without this problem. the investigators are testing whether exercise that targets this difference in movement can help reduce pain, improve function and prevent cartilage damage. there will recruit 84 patients with divided into 2 groups. 42 patients will do a 8 week exercise program on strengthening muscles responsible for extending the hip and stretching muscles that are associated with flexing the hip. the intensity of the program will change with visits to the physiotherapist through the course of their exercise program. this research hopes to develop an innovative, non-surgical, low-cost, highly feasible and accessible intervention for patients with fai.

Eligibility criteria:
inclusion criteria: * diagnosed with symptomatic fai * at least 3 months of groin pain * increased pain with hip rotation * an alpha angle greater than 60 degrees on multiplane imaging * labral tear on mri * tonnis grade of 0 or 1 exclusion criteria: * diagnosed health problems other than fai interfering with capacity to accomplish the exercise program * previous hip surgery on the affected side * surgery will happen within 6 months

Keywords: non-surgical treatment exercise
surgical transversus abdominis plane block in pediatric patients

Conditions: Child

Summary: the objective of this study to determine the effect of surgical transversus abdominis plane block and local infiltration for postoperative pain control in major abdominal surgery compare with control group.

most children experience postoperative pain after major abdominal surgery. they may have ineffective ventilation, following atelectasis and pneumonia if receive inadequate pain management. there are several methods used for pain relief such as epidural block, intravenous analgesia with local infiltration, transversus abdominis plane (tap) block by ultrasound guided and surgical tap block. therefore, the investigators would like to compare the effectiveness of postoperative pain control with tap block. however, tap block in children need experience and ultrasound. the investigators decided to do surgical tap block performing by inject from peritoneum point to skin instead.

Eligibility criteria:
inclusion criteria: 1. age \< 15 year 2. asa i-iii 3. abdominal surgery : all upper abdomen and lower abdomen which would have midline incision 4. elective surgery exclusion criteria: 1. allergic to lidocaine or bupivacaine 2. delayed development 3. major abdominal surgery within 2 year

Keywords: tap block postoperative analgesia
i-bit - evaluation of a novel binocular treatment system (i-bittm) in children with amblyopia

Conditions: Amblyopia

Summary: the study aims to determine whether 30 minutes of treatment playing an interactive computer game weekly for 6 weeks, improves visual acuity. the game has been specially configured to ensure the amblyopic eye is preferentially stimulated and the patient wears shutter glasses which manipulate the image seen by each eye in order to provide more information to the amblyopic eye. patients will be randomised to play the computer game using the i-bittm technology, play the computer game but without the i-bittm technology, or watch a dvd using the i-bittm technology.


Eligibility criteria:
inclusion criteria: * diagnosis of anisometropic, strabismic or mixed amblyopia as made by an orthoptist * male or female * aged 4 - 8 years inclusive. * participant's parent or guardian is willing and able to give informed consent for participation in the study exclusion criteria: * stimulus deprivation amblyopia. * organic lesions of the eye preventing the establishment of good vision (e.g. media opacities, abnormalities in the fundus or optic nerve). * lesions of the brain preventing the establishment of good vision (e.g. cortical visual impairment). * patients diagnosed with photosensitive epilepsy * patients diagnosed with or suspected of having conjunctivitis * loss of suppression at filter 4 or less as measured with the sbisa bar * establishment of normal vision by refractive adaptation (wearing glasses after presentation). * inability to comply with the follow up visits required * refusal to accept randomisation * have participated in a previous study examining i-bit treatment

Keywords: amblyopia i-bit tm interactive games binocular
rasagiline and apathy in parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to determine whether rasagiline is effective in the treatment of apathy in patients with parkinson's disease.

the primary objective of this study is to evaluate the efficacy of rasagiline in patients with parkinson's disease (pd) and apathy. secondary objectives are 1) to evaluate the affective and cognitive response to rasagiline and their correlates to apathy and 2) to investigate the metabolic and neurophysiologic correlates of the behavioural, cognitive and emotional, aspects of apathy in pd. this will be an exploratory, randomized, double-blind, placebo controlled, parallel-group study. 40 pd patients with apathy and without dementia will be recruited. rasagiline 1 mg or matching placebo will be administered once daily in conjunction with the subjects' usual oral antiparkinsonian medications for up to 12 weeks. patients will be evaluated at screening (-7 days) and baseline (0), as well as at weeks 4, 8, and 12. a perfusion spect will be performed at baseline and at week 12. the study will be conducted at the movement disorders unit of the neurology department at sant pau hospital (barcelona, spain).

Eligibility criteria:
inclusion criteria: * patients with idiopathic pd optimally treated for their motor deficits with stable doses of l-dopa and/or dopamine agonists and showing a non-zero score on the item 4 (motivation/initiative) of the unified parkinson's disease rating scale (updrs) exclusion criteria: * dementia associated to pd according to dsm iv criteria. history of primary psychiatric illness or axis i diagnoses according to the structured clinical interview for dsm-iv * patients complaining of acute mood or cognitive fluctuations in response to dopaminergic medication * patients treated with any mao inhibitor (including selegiline), fluoxetine and fluvoxamine during the previous month before inclusion. also will be excluded patients with a neurological disorder other than pd, any unstable systemic disease and pregnant or possibly pregnant women

Keywords: parkinson's disease apathy rasagiline
ventilator associated tracheobronchitis in the first 14 days in icu

Conditions: Airway Colonization; Tracheobronchitis and Pneumonia Associated With Ventilator

Summary: to investigate the clinical course and risk factors for vat and the impact of vat on intensive care unit (icu) morbidity and mortality.


Eligibility criteria:
inclusion criteria: * \> 48 hours mechanical ventilation exclusion criteria: * immunodeficiency * pregnancy * severe copd, chronic bronchitis, bronchiectasis * recent pneumonia

Keywords: airway colonization tracheobronchitis pneumonia
prospective and non-randomized registry of cardiocel 3d

Conditions: Intracardiac and Septal Defects; Valve and Anulus Repair; Great Vessel Reconstruction; Peripheral Vessel Reconstruction; Suture Line Buttressing

Summary: post-market, prospective, multi-centre, open-label, registry designed to collect prospective safety and performance data on the use of cardiocel in patients with cardiovascular disorders and in accordance with local standard of care. the registry will collect data with a minimum of 50 subjects per major indication (minimum total of 200) in 5-10 sites in europe. the clinical investigation will maintain data for each patient from the date of implant through 2 years post-implantation.

post-market, prospective, multi-centre, open-label, registry designed to collect prospective safety and performance data on the use of cardiocel in patients with cardiovascular disorders and in accordance with local standard of care. the registry has been designed to collect prospective product safety and performance data after the cardiocel line extension for cardiocel 3d and the indication expansion to include great vessel and peripheral reconstruction and suture line buttressing and will collect safety and performance data up to 2 years following implantation. the cardiocel 3d registry will collect data on the use of the cardiocel, cardiocel neo and cardiocel 3d for the following major indications: * intracardiac and septal defects * valve and annulus repair * great vessel reconstruction * peripheral vascular reconstruction as suture line buttressing is a procedure that does not consistently use tissue, data on this indication will only be included if available. data will be prospectively collected by the sites on registry-specific electronic case report forms (ecrfs). the primary endpoints will assess devices' safety and performance through measures and images obtained via the facility's standard of care at the respective registry site. additional data will also be collected from the implant procedure to assess user (surgeon) satisfaction with the devices' handling and performance.

Eligibility criteria:
inclusion criteria: * patient has signed the informed consent * patient is a candidate for treatment with cardiocel/cardiocel neo/cardiocel 3d per approved device indications. exclusion criteria: - no study specific exclusion criteria; patients treated per standard clinical practice
assess safety and tolerability of art-123 + folfox + bevacizumab in metastatic colorectal cancer patients

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: to evaluate the safety and tolerability of art-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab

to compare the safety and tolerability of art-123 to placebo in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab

Eligibility criteria:
inclusion criteria: * 18 years of age or older * metastatic colorectal cancer; pathologically confirmed adenocarcinoma of the colon or rectum * ecog performance status of 0 or 1 * the most recent laboratory findings (including for liver and kidney) within 14 days prior to randomization remain within acceptable ranges willingness of the patient and the sexual partner to use a highly effective contraceptive method during the course of the study * able to sufficiently understand the clinical study and give written informed consent exclusion criteria: * history of major hemorrhage * high risk of hemorrhage * history of other malignancies * active ulcer * patients using anti-coagulants and fibrinolytic drugs * active hepatitis b, or known hbs antigen positive * prior treatment history with thrombomodulin alfa * administration of another investigational medicinal product within 30 days prior to randomization * patient is pregnant (positive urine human chorionic gonadotropin) or breastfeeding or intends to get pregnant during the treatment period * patients otherwise deemed as inappropriate to participate in the study by the investigator
lubricity post-wear - competitive lenses pilot

Conditions: Refractive Error

Summary: the purpose of this study is to measure the coefficient of friction of three silicone hydrogel, daily disposable contact lenses after 16 hours of wear.

in this 3-treatment, 3-period, 6-sequence crossover study, each participant will wear all 3 products in randomized order, 1 product at a time, with a washout period of up to 7 days between treatment periods. lenses will be collected for ex-vivo lubricity analysis. the ex-vivo lubricity analysis will be conducted under a separate non-clinical protocol.

Eligibility criteria:
inclusion criteria: * must sign an informed consent form. * soft contact lens wearer (both eyes). * willing to wear study lenses at least 16 waking hours and attend all study visits. * other protocol-specified inclusion criteria may apply. exclusion criteria: * ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear. * use of systemic or ocular medications for which contact lens wear could be contraindicated. * use of artificial tears and rewetting drops during the study. * monocular (only 1 eye with functional vision) or fit with only 1 lens. * history of herpetic keratitis, ocular surgery, or irregular cornea. * pregnant. * other protocol-specified exclusion criteria may apply.

Keywords: contact lenses lubricity
randomized clinical trial of pneumatic compression device for the treatment of venous ulcers and lymphedema

Conditions: Lymphedema

Summary: the purpose of this study is to evaluate the effect of pneumatic compression in improving symptoms, quality of life and wound healing in patients with venous ulcers and/or lymphedema.

this investigation is a randomized clinical trial of a prospective cohort of an estimated 140 subjects with venous ulcers, with an observational cohort of 50 subjects with lymphedema. venous ulcer subjects will be randomized into two arms: randomization arm 1: 70 subjects with venous ulcers will receive pneumatic compression with the flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. a pre- and post-pcd treatment civiq-2 quality of life questionnaire will be administered to the subjects. for subjects with venous ulcers, wound area pre- and post-treatment will be recorded. randomization arm 2: 70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. a quality of life questionnaire will be administered at enrollment and again after one month. for subjects with venous ulcers, wound area pre- and post-treatment will be recorded. observational arm 3: 50 subjects with lymphedema will all receive pcd treatment. a pre-and post- pcd treatment civiq-2 qol questionnaire will be administered to all subjects at enrollment and again after one month of treatment.

Eligibility criteria:
inclusion criteria: * presence of a venous ulcer on the lower extremity for at least 12 weeks14 days * presence of lymphedema in the lower extremity for at least 14 days exclusion criteria: * pregnant women or women of childbearing potential not on contraception * previous use of the pneumatic compression device * class iv congestive heart failure
prognostic score in covid-19

Conditions: Covid19 Prognostic Parameters

Summary: the aim of the study is to define the clinical and biochemical parameters that characterize covid-19 patients with a negative prognostic evolution. our clinical score will be capable to recognize patient with favorable prognosis or patient with poor prognosis by statistical data analysis.


Eligibility criteria:
inclusion criteria: * patients over 18 and symptomatic and positive for covid-19 by polymerase chain reaction assay for rhino-pharingeal swab exclusion criteria: * under 18
the real-time optical diagnosis value of optical enhancement endoscopy in colorectal sessile serrated adenomas/polyps

Conditions: Colorectal Sessile Serrated Adenomas/Polyps

Summary: when a polyp is found, we begin to wash it and observe it with oe mode 1.then,the endoscopist gives a real-time optical diagnosis and the future surveillance interval.finally,the polyp will be resected for the biopsy.

when discovering a polyp, the endoscopist uses water to wash it.then, the endoscopist starts with i-scan 1 (oe mode 1) to observe the polyp closely .nextly, the endoscopist give a real-time optical diagnosis with the blind of the history of patient. considering the other polyps, the endoscopist gives a surveillance interval predictions according to the guide made by usmstf.the confidence of the real-time optical diagnosis is divided into high confidence and low confidence.after the observation, the small and diminutive polyp will be resected and have the blinded pathology.

Eligibility criteria:
inclusion criteria: 1. the high risk for colorectal cancer screening score 2. patients with colorectal polyps reviewing exclusion criteria: * 1.inflammatory bowel disease 2. polyposis syndrome 3. a history of colorectal cancer or surgical resection 4. poor bowel preparation5.not signing the informed consent 6.severe cardiopulmonary function failure lesions, severe hypertension, cerebrovascular disease, mental disorder and coma, pregnancy, lactation can't taking the colonoscopy.

Keywords: colorectal sessile serrated adenomas/polyps optical enhancement endoscopy
assessment of near vision capacity in different light intensities

Conditions: Presbyopia

Summary: patients who underwent presbyopic correction with bilateral bifocal intraocular lenses implantation are supposed to have sufficient uncorrected vision capacity for activities of daily living (adls) that require near vision acuity (nv), (ie. book reading). however, it is known that light intensity and temperature has a great impact on near vision capacity. primary objective of this study is to identify the optimal task lighting conditions (in terms of light intensity and temperature) for adls that demand near vision acuity for a sample oa patients who underwent presbyopic correction with bilateral bifocal intraocular lenses implantation


Eligibility criteria:
inclusion criteria: * presbyopia exclusion criteria: * glaucoma * corneal pathology * fundus pathology * severe neurological/mental diseases that interfere with visual acuity
study of optimal clopidogrel duration in patients receiving drug eluting stents (score trial)

Conditions: Myocardial Infarction

Summary: although the optimal duration of clopidogrel (an anti-platelet agent) therapy has been established after bare metal stent implantation in the blood vessels of the heart, there is lack of consensus regarding the optimal duration of therapy after implantation of a drug eluting stents (des). current american college of cardiology guidelines recommend clopidogrel use for at least one year in the absence of contraindications after des implantation, while recognizing that the optimal duration remains unknown. while an extended clopidogrel therapy (that is beyond the current 1 year recommendation) may increase bleeding complication, it may reduce the rates of adverse cardiovascular events like heart attacks and repeat revascularization procedures. a clinical trial which randomizes patients with an uneventful one year course after a des implantation, to an additional year of clopidogrel and aspirin therapy versus aspirin alone, will be able to answer the important question about the role of extended (2y) dual anti-platelet therapy with clopidogrel and aspirin after des implants. the investigators hypothesize that clopidogrel discontinuation at 1 year post-des implantation is associated with an increase in cardiovascular events during the one year of follow-up period.

score is a multicenter, prospective randomized study of post-percutaneous coronary intervention (pci) patients with an uneventful 1 year post-pci course on dual anti-platelet therapy (dapt) with clopidogrel and aspirin. patient will be randomized to an additional 1 year of dapt (treatment arm) vs. aspirin alone (control arm)to assess the following endpoints during the 1 year follow-up period: 1. death / myocardial infarction (mi) (primary end-point) 2. combined endpoints of death, myocardial infarction, repeat revascularization, stroke, and major/minor bleeding (secondary end-point) during the year of follow up, subjects will be contacted once every three months. this will enable us to track study endpoints in the study population. in addition the patients' medical records will be screened to investigate if any of the aforementioned endpoints have been reached.

Eligibility criteria:
inclusion criteria: * post-pci patients receiving at least 1 des * completed 9-15 months follow-up free of mi, repeat revascularization * able to provide informed consent * have continued dual anti-platelet therapy with aspirin and clopidogrel for 1 year post-pci exclusion criteria: * patients allergic to aspirin * patients with aspirin resistance * patients with allergy to clopidogrel * patients on concomitant warfarin therapy * history of bleeding diathesis, coagulopathy, and/or platelet count \< 100,000 cubic mm * patients with a life expectancy less than 1 year due to active cancers (except basal cell carcinoma) * pregnancy

Keywords: drug eluting stent clopidogrel optimal duration of clopidogrel post des stent implantation
study on the correlation of free vitamin d with bmd and fracture

Conditions: Osteoporosis

Summary: according to the free hormone hypothesis, the biological activity of a hormone is carried by the portion that is not bound to protein or its carrier in circulation. based on this, we believe that the free vitamin d, which is the proportion of vitamin d unbound to vitamin d binding protein and albumin, performs the calcium-regulating functions of the vitamin. hence, our objective is to study whether free vitamin correlated better with bmd and fracture than the total vitamin d.

osteoporosis is a major health issue worldwide as it increases the risk of fragility fracture and chronic disability. the studies on the association between vitamin d and osteoporosis have yielded conflicting results. while some have shown a positive correlation, others have concluded that there is no association at all. recent reports have shown vitamin d supplementation do not prevent fragile fractures. this might be because the actual vitamin d status, which should be the free vitamin d, has not been measured.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of osteoporosis and with or without fracture * post- menopausal women * age \> 48 years exclusion criteria: * vitamin d supplementation in recent 6 months * patients on steroid * age \< 48 years * patients with chronic diseases such as liver cirrhosis, renal failure, hypertension, hyperparathyroidism